AA
GMAB icon

Ancora Advisors’s Genmab GMAB Stock Holding History

Ancora Advisors’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.19K Sell
119
-519
-81% -$15.6K ﹤0.01% 2065
2025
Q4 		$19.6K Buy
+638
New +$19.9K ﹤0.01% 1567

Other funds holding GMAB

OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
HL
Harding Loevner Bridgewater, New Jersey $9.72B AUM 22.38% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Ancora Advisors's GMAB Position: Q1 2026 in Review

Ancora Advisors reduced its Genmab (GMAB) stake by 81% in Q1 2026, selling an estimated $15.6K and leaving 119 shares worth $3.19K. The position accounts for ﹤0.01% of the portfolio, ranked #2065.

Ancora Advisors first reported a position in GMAB in Q4 2025 and has held it in 2 quarters since. The position peaked at $19.6K in Q4 2025. 272 funds tracked by Wall St. Rank hold GMAB as of Q1 2026.

  • Ancora Advisors held 119 shares of Genmab worth $3.19K as of Q1 2026.
  • Ancora Advisors sold 519 Genmab shares in Q1 2026, an estimated $15.6K.
  • Genmab made up ﹤0.01% of Ancora Advisors's portfolio in Q1 2026, its #2065 holding.
  • Ancora Advisors first reported a position in Genmab in Q4 2025 and has held it in 2 quarters since.
  • Ancora Advisors's Genmab position peaked at $19.6K in Q4 2025.
  • 272 funds tracked by Wall St. Rank held Genmab as of Q1 2026.

Based on Ancora Advisors's 13F filing for Q1 2026, filed 15 May 2026.